| Issue |
Section |
Title |
File |
| No 4 (2012) |
Articles |
HIV AS AN INDEPENDENT RISK FACTOR FOR CARDIOVASCULAR DISEASES |
|
| No 1 (2013) |
Articles |
USE OF THE FUSION INHIBITOR ENFUVIRTIDE IN ANTIRETROVIRAL THERAPY REGIMENS FOR HIV-INFECTED PATIENTS |
|
| No 2 (2013) |
Articles |
THE HEPATITIS C VIRUS PROTEASE INHIBITOR TELAPREVIR IN THERAPY REGIMENS FOR CHRONIC HEPATITIS C IN PATIENTS WITH HIV INFECTION |
|
| No 2 (2013) |
Articles |
ROLE OF RISK FACTORS IN THE DEVELOPMENT OF CARDIOVASCULAR DISEASE IN HIV-INFECTED PATIENTS WITH THE NATURAL HISTORY OF HIV INFECTION |
|
| No 4 (2013) |
Articles |
GENDER FEATURES OF THE DEVELOPMENT OF CARDIOVASCULAR RISKS IN HIV-INFECTED PATIENTS NOT RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY |
|
| No 6 (2014) |
Articles |
DUAL ANTIRETROVIRAL THERAPY WITH LOPINAVIR AND RITONAVIR |
|
| No 1 (2015) |
Articles |
Hepatotoxicity of antiretroviral therapy in HIV-infected patients |
|
| No 2 (2015) |
Articles |
EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY REGIMENS CONTAINING ETRAVIRINE FOR HIV-INFECTED PATIENTS |
|
| No 3 (2015) |
Articles |
Antiretroviral therapy regimens containing the HIV protease inhibitor saquinavir |
|
| No 6 (2015) |
Articles |
HIV drug resistance: Dolutegravir is a second-generation HIV integrase inhibitor |
|
| No 5 (2016) |
Articles |
The efficacy and safety of Elpivirine as part of a 24-48-week antiretroviral therapy regimen versus an Efavirenz-containing regimen |
|
| No 1 (2011) |
Articles |
MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME DURING ANTIRETROVIRAL THERAPY IN PATIENTS WITH HIV INFECTION |
|
| No 2 (2011) |
Articles |
THE HIV NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ABACAVIR AND LAMIVUDINE IN FIRST-LINE ANTIRETROVIRAL THERAPY REGIMENS |
|
| Vol 10, No 3 (2020) |
Articles |
TUBERCULOSIS TRENDS IN HIV-INFECTED PATIENTS IN THE CISCOUNTRIES IN 2014-2018 |
|
| Vol 10, No 3 (2020) |
Articles |
CAUSES OF DEATHS AMONG HIV-INFECTED PERSONS IN THE RUSSIAN FEDERATION IN 2008-2018 |
|
| Vol 10, No 3 (2020) |
Articles |
QUALITY OF ANTIRETROVIRAL THERAPY IN 2008-2018 |
|
| Vol 10, No 3 (2020) |
Articles |
THE PROBLEM OF BODY WEIGHT GAIN IN HIV-INFECTED PATIENTS DURING ANTIRETROVIRAL THERAPY |
|
| Vol 11, No 3 (2021) |
Articles |
Antiretroviral therapy in Russia |
|
| Vol 11, No 3 (2021) |
Articles |
HIV-1 drug resistance in patients with virological inefficiency on ART in Russia in 2013-2021 |
|
| Vol 11, No 3 (2021) |
Articles |
Multidrug-resistant tuberculosis in patients with HIV infection in the CIS countries |
|
| Vol 11, No 3 (2021) |
Articles |
Results of treatment with a 60-week Russian ART regimen in patients with HIV infection |
|
| Vol 11, No 4 (2021) |
Articles |
The clinical course of HIV/ COVID-19 co-infection and approaches to its therapy |
|
| Vol 11, No 4 (2021) |
Articles |
Randomized, open-label, controlled, comparative study on switching HIV-infected patients with their antiretroviral therapy experience to a DTG and 3TC regimen: 96-weeks results |
|
| Vol 12, No 3 (2022) |
Articles |
Risk factors for tuberculosis in patients with HIV infection |
|
| Vol 12, No 3 (2022) |
Articles |
The efficiency and safety of ART after switching patients to the combined Russian NRTI phosphaladine in combination with elsulfavirine |
|
| Vol 13, No 3 (2023) |
Epidemic Situation |
Impact of antiretroviral therapy on the development of the HIV-infection epidemic in the Russian Federation |
|
| Vol 13, No 3 (2023) |
Original Investigations |
Causes of death in persons infected with the human immunodeficiency virus |
|
| Vol 13, No 3 (2023) |
Original Investigations |
Results of cognitive function screening in HIV-infected patients taking antiretroviral therapy |
|
| Vol 14, No 3 (2024) |
Original Investigations |
Assessment of cardiovascular risk in HIV-positive individuals with latent tuberculosis infection |
|
| Vol 14, No 3 (2024) |
Exchange of Experience |
Results of post-registration study of efficacy and safety of antiretroviral therapy schemes including elsulfavirine in previously non-treated HIV-infected patients (PASS-1) |
|
